About this trial
The goal of this clinical trial is to ensure that contact dermatitis is not prohibiting any person with diabetes the access to the optimal treatment.
The main questions this study aims to answer are:
1. How many pediatric patients with contact dermatitis due to diabetes devices experience recurrence of contact dermatitis depending on which type of patch they use under their device. 2. Is one type of patch (silicone-based vs. hydrocolloid patch) better than the other at preventing contact dermatitis? The group being investigated is children and adolescents aged 2-18 years with contact dermatitis caused by either an insulin pump or a continuous glucose monitor.
The participants will be asked to do different surveys on well-being and they will go to three physical visits. At the visits the the following will happen:
* clinical skin examination * skin picture (of last used pump and sensor site as well as reportet skin reactions) * height and weight * blodsample (HbA1c and fillagrin mutations) * interview on skin reactions etc. * ultrasound of the skin * tape strips of the skin * EIS (transmit harmless electrical signal through the skin)
Eligibility criteria
Qualifiers
Any type of contact dermatitis due to either insulin pump or glucose sensor
Being between 2-18 years of age prior to inclusion
Disqualifiers
Those who are unable to read and understand Danish and/or have impaired cognitive development that may interfere with the ability to answer questionnaires in Danish and/or be reached by phone or videocall.
Trial design
Treatments tested in this trial
- hydrocolloid patch as patch used in the Sandwich method
- Silicone-based patch as patch used in the Sandwitch method